HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc. Dr. Forsythe brings over thirty years of medical and research experience including expertise in the research and clinical application of his “Forsythe Immune Therapy” (FIT).
As previously announced, James W. Forsythe, MD, HMD, board certified oncologist and a member of HST Global Inc.’s Board of Directors and Head of the Scientific Advisory Board, was featured in Suzanne Somers’ book Knockout. Due to the overwhelming response to the information and protocol featured in Ms. Somers’ book, Dr. Forsythe’s clinic has become inundated with new patient requests and referrals. Due to this dramatic increase in both new patient inquiries and volume, it has become necessary to increase the staff at Dr Forsythe’s facility, The Cancer Screening and Treatment Center of Nevada.
With the increase in new patient inquiries coupled with the demonstrated efficacy of Dr. Forsythe’s protocol, HST Global intends to expedite the opening of its FIT Certified clinics. In a focused effort to properly train the physicians and support staff in these clinics, HST Global and Dr. Forsythe have agreed to develop and implement the curriculum for the licensing and/or certification of physicians and support staff in the administration of Dr. Forsythe’s FIT protocol.
"We are excited to see the increase in interest from people both across the country and internationally since Dr. Forsythe was featured in Ms. Somers’ book,” said Ron Howell, CEO and President of HST Global, Inc. “The need to add additional staff to the clinic is a testimony to both the success of the book as well as a confirmation of strong interest in the FIT protocol.” Mr. Howell further stated: "James will be an integral part of the development of this curriculum, ensuring that as new clinics are opened, we have properly trained physicians and personnel staffing these facilities.”
Currently, Dr. Forsythe is an Associate Professor of Medicine and Pathology, University of Nevada Medical School Reno, NV. Prior to that, he was an instructor in Medicine and Hematology, University of California Medical Center, San Francisco, CA. Dr. Forsythe currently serves on HST Global Inc.’s Scientific Advisory Board. He received his Doctorate of Medicine from the University of California, San Francisco and his Undergraduate Degree from University of California at Berkeley. Dr. Forsythe is certified in Homeopathy and Board Certified in Internal Medicine, Medical Oncology and Utilization Review and Quality Assurance. He is also Board eligible in Clinical Pathology and Medical Gerontology. Dr. Forsythe is also the owner and Medical Director of Cancer Screening and Treatment Center of Nevada and Century Wellness Clinic. In addition, Dr. Forsythe spent 26 years in the United States Army Medical Corps, retiring full Colonel. He was also the former State Surgeon in the Nevada Army National Guard.
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.